Fresenius Medical Care Stock EBITDA

FMS Stock

USD 22.78 0.76 3.45%

Fresenius Medical Care fundamentals help investors to digest information that contributes to Fresenius Medical's financial success or failures. It also enables traders to predict the movement of Fresenius Stock. The fundamental analysis module provides a way to measure Fresenius Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fresenius Medical stock.

		Last Reported	Projected for Next Year
	EBITDA	3.2 B	2.2 B

EBITDA is likely to drop to about 2.2 B in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Fresenius Medical Care Company EBITDA Analysis

Fresenius Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Fresenius Medical EBITDA

3.21 B

Most of Fresenius Medical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fresenius Medical Care is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Fresenius EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Fresenius Medical is extremely important. It helps to project a fair market value of Fresenius Stock properly, considering its historical fundamentals such as EBITDA. Since Fresenius Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fresenius Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fresenius Medical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Property Plant Equipment	Good Will	Short Term Investments	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Treasury Stock	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Cash And Equivalents	Net Working Capital	Capital Stock
Total Assets		0.98	0.94	0.87	0.95	0.85	0.99	0.96	0.77	-0.34	0.51	0.03	0.45	0.74	0.91	0.56	0.04	0.39	-0.72	0.36	0.63	-0.65	0.12	0.07	0.16	-0.21
Total Stockholder Equity	0.98		0.86	0.86	0.96	0.86	0.95	0.97	0.8	-0.37	0.53	0.0	0.38	0.68	0.91	0.53	0.14	0.33	-0.73	0.49	0.52	-0.61	0.15	0.22	0.2	-0.18
Net Debt	0.94	0.86		0.77	0.83	0.73	0.97	0.82	0.69	-0.23	0.4	0.04	0.52	0.76	0.82	0.52	-0.11	0.36	-0.61	0.09	0.76	-0.64	0.09	-0.2	-0.03	-0.19
Retained Earnings	0.87	0.86	0.77		0.85	0.75	0.85	0.85	0.66	-0.35	0.5	-0.03	0.36	0.88	0.97	0.61	-0.01	0.47	-0.79	0.36	0.61	-0.83	0.19	0.15	0.26	-0.59
Accounts Payable	0.95	0.96	0.83	0.85		0.95	0.92	0.97	0.7	-0.45	0.62	0.21	0.51	0.6	0.92	0.61	0.03	0.3	-0.76	0.56	0.41	-0.51	0.15	0.15	0.15	-0.12
Net Receivables	0.85	0.86	0.73	0.75	0.95		0.83	0.91	0.6	-0.47	0.63	0.37	0.61	0.44	0.85	0.63	-0.09	0.22	-0.77	0.59	0.22	-0.32	0.1	0.14	0.04	0.0
Total Liab	0.99	0.95	0.97	0.85	0.92	0.83		0.93	0.74	-0.32	0.49	0.07	0.49	0.76	0.89	0.57	-0.03	0.39	-0.71	0.28	0.68	-0.67	0.09	-0.02	0.09	-0.21
Total Current Assets	0.96	0.97	0.82	0.85	0.97	0.91	0.93		0.72	-0.36	0.54	0.08	0.48	0.63	0.9	0.56	0.08	0.41	-0.74	0.49	0.47	-0.56	0.13	0.24	0.29	-0.18
Short Term Debt	0.77	0.8	0.69	0.66	0.7	0.6	0.74	0.72		-0.02	0.14	-0.34	-0.02	0.59	0.66	0.23	0.41	0.04	-0.43	0.47	0.39	-0.53	0.06	0.32	-0.15	-0.08
Intangible Assets	-0.34	-0.37	-0.23	-0.35	-0.45	-0.47	-0.32	-0.36	-0.02		-0.94	-0.56	-0.4	-0.16	-0.42	-0.34	0.08	-0.1	0.46	-0.33	0.0	0.12	-0.04	-0.14	-0.05	0.03
Common Stock	0.51	0.53	0.4	0.5	0.62	0.63	0.49	0.54	0.14	-0.94		0.6	0.42	0.27	0.58	0.58	-0.22	0.29	-0.65	0.42	0.14	-0.22	0.08	0.08	0.12	-0.08
Current Deferred Revenue	0.03	0.0	0.04	-0.03	0.21	0.37	0.07	0.08	-0.34	-0.56	0.6		0.53	-0.29	0.08	0.54	-0.52	-0.08	-0.24	0.19	-0.26	0.31	-0.27	-0.18	-0.24	0.34
Long Term Debt	0.45	0.38	0.52	0.36	0.51	0.61	0.49	0.48	-0.02	-0.4	0.42	0.53		0.23	0.48	0.36	-0.37	0.16	-0.35	-0.11	0.2	-0.05	0.0	-0.23	0.02	0.01
Property Plant Equipment	0.74	0.68	0.76	0.88	0.6	0.44	0.76	0.63	0.59	-0.16	0.27	-0.29	0.23		0.81	0.4	-0.03	0.54	-0.56	-0.03	0.85	-0.93	0.25	-0.1	0.23	-0.75
Good Will	0.91	0.91	0.82	0.97	0.92	0.85	0.89	0.9	0.66	-0.42	0.58	0.08	0.48	0.81		0.65	-0.09	0.43	-0.83	0.4	0.55	-0.7	0.21	0.08	0.22	-0.45
Short Term Investments	0.56	0.53	0.52	0.61	0.61	0.63	0.57	0.56	0.23	-0.34	0.58	0.54	0.36	0.4	0.65		-0.52	0.39	-0.74	0.28	0.33	-0.35	0.11	-0.04	0.08	-0.21
Net Tangible Assets	0.04	0.14	-0.11	-0.01	0.03	-0.09	-0.03	0.08	0.41	0.08	-0.22	-0.52	-0.37	-0.03	-0.09	-0.52		-0.45	0.28	0.37	-0.18	-0.09	0.0	0.63	0.06	0.14
Long Term Investments	0.39	0.33	0.36	0.47	0.3	0.22	0.39	0.41	0.04	-0.1	0.29	-0.08	0.16	0.54	0.43	0.39	-0.45		-0.41	-0.2	0.64	-0.49	0.24	-0.17	0.64	-0.61
Short Long Term Debt	-0.72	-0.73	-0.61	-0.79	-0.76	-0.77	-0.71	-0.74	-0.43	0.46	-0.65	-0.24	-0.35	-0.56	-0.83	-0.74	0.28	-0.41		-0.46	-0.34	0.53	-0.15	-0.09	-0.2	0.34
Treasury Stock	0.36	0.49	0.09	0.36	0.56	0.59	0.28	0.49	0.47	-0.33	0.42	0.19	-0.11	-0.03	0.4	0.28	0.37	-0.2	-0.46		-0.34	-0.04	0.02	0.51	0.03	0.19
Long Term Debt Total	0.63	0.52	0.76	0.61	0.41	0.22	0.68	0.47	0.39	0.0	0.14	-0.26	0.2	0.85	0.55	0.33	-0.18	0.64	-0.34	-0.34		-0.79	0.21	-0.39	0.27	-0.58
Capital Surpluse	-0.65	-0.61	-0.64	-0.83	-0.51	-0.32	-0.67	-0.56	-0.53	0.12	-0.22	0.31	-0.05	-0.93	-0.7	-0.35	-0.09	-0.49	0.53	-0.04	-0.79		-0.07	-0.01	-0.27	0.75
Net Invested Capital	0.12	0.15	0.09	0.19	0.15	0.1	0.09	0.13	0.06	-0.04	0.08	-0.27	0.0	0.25	0.21	0.11	0.0	0.24	-0.15	0.02	0.21	-0.07		-0.09	0.44	-0.29
Cash And Equivalents	0.07	0.22	-0.2	0.15	0.15	0.14	-0.02	0.24	0.32	-0.14	0.08	-0.18	-0.23	-0.1	0.08	-0.04	0.63	-0.17	-0.09	0.51	-0.39	-0.01	-0.09		0.2	0.08
Net Working Capital	0.16	0.2	-0.03	0.26	0.15	0.04	0.09	0.29	-0.15	-0.05	0.12	-0.24	0.02	0.23	0.22	0.08	0.06	0.64	-0.2	0.03	0.27	-0.27	0.44	0.2		-0.49
Capital Stock	-0.21	-0.18	-0.19	-0.59	-0.12	0.0	-0.21	-0.18	-0.08	0.03	-0.08	0.34	0.01	-0.75	-0.45	-0.21	0.14	-0.61	0.34	0.19	-0.58	0.75	-0.29	0.08	-0.49

Click cells to compare fundamentals

Fresenius EBITDA Historical Pattern

Today, most investors in Fresenius Medical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Fresenius Medical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Fresenius Medical ebitda as a starting point in their analysis.

Fresenius Medical EBITDA

Timeline

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Fresenius Medical

Ebitda Over Time

Fresenius Ebitda

Ebitda

2.21 Billion

At this time, Fresenius Medical's EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Fresenius Medical Care reported earnings before interest,tax, depreciation and amortization of 3.21 B. This is 265.8% higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 17.67% higher than that of the company.

Fresenius EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fresenius Medical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fresenius Medical could also be used in its relative valuation, which is a method of valuing Fresenius Medical by comparing valuation metrics of similar companies.

Fresenius Medical is currently under evaluation in ebitda category among its peers.

Fresenius Medical Current Valuation Drivers

We derive many important indicators used in calculating different scores of Fresenius Medical from analyzing Fresenius Medical's financial statements. These drivers represent accounts that assess Fresenius Medical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Fresenius Medical's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	9.9B	10.0B	8.4B	4.5B	5.6B	9.1B
Enterprise Value	22.7B	21.3B	20.2B	16.4B	16.3B	13.9B

Fresenius Medical ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fresenius Medical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fresenius Medical's managers, analysts, and investors.

Environmental

Governance

Social

Fresenius Medical Institutional Holders

Institutional Holdings refers to the ownership stake in Fresenius Medical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fresenius Medical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fresenius Medical's value.

		Shares
Visionpoint Advisory Group, Llc	2024-09-30	146.4 K
Two Sigma Investments Llc	2024-09-30	138.6 K
Quantinno Capital Management Lp	2024-09-30	110.1 K
Geode Capital Management, Llc	2024-09-30	90.8 K
Jane Street Group Llc	2024-06-30	86.1 K
Ci Private Wealth Llc	2024-09-30	85.5 K
Fmr Inc	2024-09-30	76.4 K
Franklin Resources Inc	2024-09-30	74.6 K
Nuveen Asset Management, Llc	2024-09-30	73.9 K
Pzena Investment Management, Llc	2024-09-30	16.2 M
Fiduciary Management, Inc. Of Milwaukee	2024-09-30	6.6 M

Fresenius Fundamentals

	Return On Equity	0.0582
	Return On Asset	0.0298
	Profit Margin	0.03 %
	Operating Margin	0.08 %
	Current Valuation	24.18 B
	Shares Outstanding	586.83 M
	Shares Owned By Institutions	7.39 %
	Number Of Shares Shorted	1.02 M
	Price To Earning	6.53 X
	Price To Book	0.90 X
	Price To Sales	0.68 X
	Revenue	19.45 B
	Gross Profit	5.31 B
	EBITDA	3.21 B
	Net Income	732.46 M
	Cash And Equivalents	362.77 M
	Cash Per Share	1.75 X
	Total Debt	12.05 B
	Debt To Equity	0.88 %
	Current Ratio	1.18 X
	Book Value Per Share	46.43 X
	Cash Flow From Operations	2.63 B
	Short Ratio	3.11 X
	Earnings Per Share	1.19 X
	Price To Earnings To Growth	0.45 X
	Target Price	21.25
	Number Of Employees	113.08 K
	Beta	0.85
	Market Capitalization	13.18 B
	Total Asset	33.93 B
	Retained Earnings	10.92 B
	Working Capital	2.59 B
	Current Asset	6.98 B
	Current Liabilities	4.19 B
	Annual Yield	0.03 %
	Five Year Return	1.29 %
	Net Asset	33.93 B
	Last Dividend Paid	1.19

About Fresenius Medical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Fresenius Medical Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fresenius Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fresenius Medical Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Fresenius Stock Analysis

When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC